Does topical diclofenac relieve osteoarthritis pain? by Hodge, Bryan & Skolnik, Deborah C.
Evidence-based answers from the 
Family Physicians Inquiries Network
124 ThE JourNal oF FamIly PracTIcE  |   FEBruary 2015  |   Vol 64, No 2
clinical inquiries
Bryan Hodge, DO
Hendersonville  
Family Medicine Residency 
Program, Mountain Area 
Health Education Center, 
University of North  
Carolina, Hendersonville
Debbie Skolnik, MLS 
Mountain Area Health 
Education Center,  
Asheville, NC
ASSiStAnt EDitOR
Anne Mounsey, MD
University of North  
Carolina School of  
Medicine, Chapel Hill
EvidEncE-basEd answEr
A
	 Does	topical	diclofenac		
relieve	osteoarthritis	pain?	
	 	 		Yes,	at	least	in	the	short	term.	Topi-
	 	 	 cal	 diclofenac,	 with	 and	 without	 di-
methyl	 sulfoxide	 (DMSO),	 modestly	 im-
proves	pain	and	 function	scores	 (by	4%-8%)	
for	 as	 long	 as	 12	weeks	 in	 patients	with	 os-
teoarthritis	(OA)	of	the	knee	(strength	of	rec-
ommendation	 [SOR]:	 A,	 meta-analyses	 of	
multiple	randomized	controlled	trials	[RCTs]).
Topical	diclofenac	modestly	decreas-
es	 pain	 scores	 in	patients	with	OA	of	 the	
hand	in	the	short	term	(by	9%	at	6	weeks)	
but	 no	 more	 than	 placebo	 at	 8	 weeks	
(SOR:	B,	RCT).	
Both	 topical	 diclofenac	 with	 DMSO	
and	 oral	 diclofenac	 produce	 similar	 pain	
and	 function	 scores	 in	 patients	 with	 OA	
of	 the	 knee.	 In	 addition	 to	 minor	 skin	
dryness,	 topical	diclofenac	causes	gastro-
intestinal	 (GI)	 adverse	 effects	 in	 about	 a	
third	of	patients (SOR:	B,	RCT).	
Evidence summary 
Diclofenac	gel	($260-$330	per	150-mL	bottle)	
and	diclofenac	with	DMSO	 solution	 are	 the	
only	 topical	 nonsteroidal	 anti-inflammatory	
drugs	(NSAIDs)	available	in	the	United	States.	
topical diclofenac with DMSO  
beats placebo
In	 a	 meta-analysis	 of	 3	 RCTs	 (697	 pa-
tients,	 mean	 age	 63.2,	 37%	 male)	 with	
knee	 OA,	 topical	 diclofenac	 solution	 with	
DMSO	 (Pennsaid,	 40	drops	 applied	4	 times	
daily)	 demonstrated	 superiority	 to	 vehicle-
controlled	 placebo	 at	 4	 to	 12	 weeks	 (mean	
8.5	 weeks)	 using	 the	 Western	 Ontario	 and	
McMaster	 Universities	 (WOMAC)	 Osteoar-
thritis	Index.1	The	WOMAC	is	a	standardized	
patient	questionnaire	measuring	5	items	for	
pain	(score	range	0-20),	2	for	stiffness	(score	
range	 0-8),	 and	 17	 for	 functional	 limitation	
(score	range	0-68).
Compared	 with	 placebo,	 topical	 diclof-
enac	with	DMSO	resulted	in	1.6	units	greater	
reduction	 in	 pain	 (8%	 difference),	 0.6	 units	
greater	 reduction	 in	 stiffness	 (7.5%	 differ-
ence),	and	5.5	units	greater	 improvement	 in	
physical	 function	 (8%	 difference).	 Patients	
using	 diclofenac	 reported	 more	 minor	 skin	
dryness	than	patients	using	placebo	(number	
needed	to	harm	[NNH]=6).		
Diclofenac gel is also effective,  
but may cause dermatitis 
A	pooled	analysis	of	3	12-week	randomized,	
double-blind,	 parallel-group,	 multicenter	
trials	 of	 1426	patients	with	OA	of	 the	 knee	
compared	 topical	 diclofenac	 gel	 (4	 g	 ap-
plied	 4	 times	 a	 day)	 with	 vehicle	 placebo	
for	patients	older	than	25	years	and	patients	
older	than	65	years.2	Investigators	evaluated	
972	patients	who	 suffered	a	 symptom	flare	
at	 1,	 4,	 8,	 and	 12	 weeks	 after	 a	 one-week	
washout	period.	
Diclofenac	 demonstrated	 statistical	 su-
periority	 across	 all	 age	 groups	 when	 com-
pared	 with	 placebo,	 based	 on	 pain	 and	
physical	 function	measured	on	the	WOMAC	
Index.	Its	effects	were	modest,	however.	
At	 12	 weeks,	 patients	 younger	 than	
65	years	showed	pain	improvement	of	-5.8	vs	
-4.7	 for	placebo	(a	5.5%	improvement	on	the	
20-point	 scale)	and	 improvement	 in	physical	
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function	of	-17.9	vs	-14.2	(a	5.4%	improvement	
on	 the	 68-point	 scale).	 Patients	 older	 than	
65	 years	 demonstrated	pain	 improvement	 of	
-5.3	vs	 -4.1	 for	placebo	 (6%	 improvement	on	
the	20-point	scale)	and	physical	function	im-
provement	of	-15.5	vs	-11.0	for	placebo	(6.6%	
improvement	on	the	68-point	scale).	
Dermatitis	was	more	common	in	the	di-
clofenac	groups,	with	a	NNH	of	30	in	patients	
younger	than	65	years	and	19	in	patients	old-
er	than	65	years.
Diclofenac	 gel	 effectively	 treated	 hand	
OA	 for	as	 long	as	6	weeks	 in	a	 randomized,	
double-blind,	 placebo-controlled	 trial	 of	
809	 men	 and	 women	 older	 than	 39	 years.	
Pain	 scores	 on	 a	 100-point	 visual	 analog	
scale	 improved	 when	 compared	 with	 pla-
cebo	 alone.3	 At	 6	 weeks,	 topical	 diclofenac	
reduced	pain	scores	by	45%	compared	with	
36%	 for	 placebo	 (P=.023).	 Pain	 reductions	
also	were	greater	 in	 the	diclofenac	group	at	
8	weeks,	although	not	statistically	different.
Oral diclofenac works well, too, 
but has more Gi adverse effects
An	RCT	of	 622	patients	 (40-85	 years	 of	 age)	
with	 symptomatic	 and	 radiographically	 di-
agnosed	 OA	 of	 the	 knee	 compared	 topical	
diclofenac	 solution	 (75	 mg/d)	 with	 oral	 di-
clofenac	 (50	 mg	 3	 times	 a	 day)	 and	 found	
similar	 efficacy	 at	 12	 weeks,	 with	 no	 sig-
nificant	difference	between	oral	 and	 topical	
preparations	for	pain,	physical	function,	and	
stiffness	measured	 with	 the	WOMAC	 Index	
(P=.23,	.06,	.24,	respectively).4	Oral	diclofenac	
produced	more	adverse	GI	 side	effects	 than	
the	topical	solution	(48%	vs	35%;	P=.0006).	
Recommendations
The	 Agency	 for	 Healthcare	 Research	 and	
Quality	 states	 that	 topical	 and	 oral	 NSAIDs	
reduce	knee	OA	pain	equally.5		
The	Guidelines	of	the	American	Academy	
of	Orthopaedic	Surgeons,	American	College	
of	Rheumatology,	 European	League	Against	
Rheumatism,	 Osteoarthritis	 Research	 Soci-
ety	 International,	 and	 National	 Institute	 for	
Health	and	Care	Excellence	all	state	that	cli-
nicians	may	consider	topical	NSAIDs	for	pa-
tients	with	mild	to	moderate	OA	of	the	knee	
or	hand,	particularly	in	patients	with	few	af-
fected	joints	or	a	history	of	sensitivity	to	oral	
NSAIDs.6		 	 	 																						JFP
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